City of Hope Advances Precision Oncology with ASCO 2026 Data on Microbiome, Bispecific Antibodies, and Novel Therapies
Event summary
- City of Hope presents 49 abstracts at ASCO 2026, spanning targeted therapies, microbiome science, and blood cancers.
- Gut microbiome patterns linked to immunotherapy response in advanced kidney cancer, with 66.7% objective response rate in combination therapy.
- Bispecific antibody combination shows 70.3% response rate in relapsed large B-cell lymphoma, outperforming standard chemotherapy.
- First-in-class Wnt pathway inhibitor demonstrates 22% response rate in advanced liver cancer.
- First-in-human study of dual-targeting antibody-drug conjugate achieves 45% response rate in metastatic prostate cancer.
The big picture
City of Hope's ASCO 2026 presentations highlight the growing role of precision oncology, particularly in leveraging microbiome data and novel antibody-based therapies. The findings underscore a shift toward personalized treatment approaches in cancer care, with potential implications for both regulatory pathways and competitive dynamics in the oncology space. The organization's focus on biomarker-driven strategies aligns with broader industry trends toward more targeted and effective cancer therapies.
What we're watching
- Clinical Validation
- Whether microbiome-based treatment stratification will gain regulatory approval and clinical adoption.
- Therapeutic Positioning
- How bispecific antibody combinations will be integrated into treatment algorithms for lymphoma.
- Pipeline Progression
- The pace at which Wnt pathway inhibitors advance through later-stage trials for liver cancer.
Related topics